159 related articles for article (PubMed ID: 35872544)
1. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
[TBL] [Abstract][Full Text] [Related]
2. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
4. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
5. Trk kinase inhibitors as new treatments for cancer and pain.
Wang T; Yu D; Lamb ML
Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
Panchal I; Tripathi RKP; Parmar K; Yadav MR
Curr Top Med Chem; 2024; 24(1):3-30. PubMed ID: 38058091
[TBL] [Abstract][Full Text] [Related]
7. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
8. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development.
Bernard-Gauthier V; Mahringer A; Vesnaver M; Fricker G; Schirrmacher R
Bioorg Med Chem Lett; 2017 Jun; 27(12):2771-2775. PubMed ID: 28476569
[TBL] [Abstract][Full Text] [Related]
11. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
[TBL] [Abstract][Full Text] [Related]
13. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma.
Jin W; Lee JJ; Kim MS; Son BH; Cho YK; Kim HP
Biochem Biophys Res Commun; 2011 Mar; 406(1):89-95. PubMed ID: 21295543
[TBL] [Abstract][Full Text] [Related]
15. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
[TBL] [Abstract][Full Text] [Related]
16. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophin receptor genes are expressed in distinct patterns in developing dorsal root ganglia.
Mu X; Silos-Santiago I; Carroll SL; Snider WD
J Neurosci; 1993 Sep; 13(9):4029-41. PubMed ID: 8366358
[TBL] [Abstract][Full Text] [Related]
18. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
[TBL] [Abstract][Full Text] [Related]
19. Expression of trkA, trkB, and trkC in injured and regenerating retinal ganglion cells of adult rats.
Cui Q; Tang LS; Hu B; So KF; Yip HK
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1954-64. PubMed ID: 12037005
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
